Physician profile

Rachael Schultz

Harrisburg, PA

NPI 1386224269

$163.97

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$163.97

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $41.68 2024 Prolia, Evenity
Dexcom, INC. $21.37 2024 Dexcom G6 Transmitter
Astrazeneca Pharmaceuticals LP $18.85 2024 Farxiga
Esperion Therapeutics, INC. $17.70 2024 Nexletol
Lilly USA, LLC $17.67 2024 Jardiance
Exact Sciences Corporation $16.33 2024 Cologuard Collection Kit
Idorsia Pharmaceuticals US INC $15.76 2024 Quviviq
Novo Nordisk INC $14.61 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rachael Schultz

$163.97

in general payments reported 2019-2025

Years
2024
Top company
Amgen INC.

https://glasscript.com/doctor/11686900/rachael-schultz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.